SARS-CoV-2/ACE-2 pseudovirus entry blocking assay

The spike glypcoprotein S of SARS-CoV-2 uses the human Angiotensin Converting Enzyme 2 (ACE2) as an entry receptor and recognizes it with a similar affinity to the 2002–2003 SARS-CoV isolates, which suggests it can spread efficiently in humans, in agreement with the numerous SARS-CoV-2 human-to-human transmission events reported to date (Walls et al., 2020).

Figure 1. Graphical abstract modified from Walls et al. (2020).

In collaboration with its academic partners at the PSI, InterAx Biotech is establishing a pseudovirus entry assay using murine leukemia virus based pseudotyped particles expressing the SARS-CoV-2 spike protein (and other relevant SARS-CoV-2 envelope proteins). The assay is described in detail in Walls et al. (2020) and Millet et al. (2016, 2019) and will enable a medium-throughput (96 well format) screen for blocking the interaction of the SARS-CoV-2 spike glycoprotein (and other envelope proteins) and the human ACE2 expressed in a host target cell line. This assay is suitable to be performed in the BSL-2 facilities at PSI and non-infective compounds ranging from small molecules to antibody sera can be tested. For detailed information please send an Email to contact@interaxbiotech.com with COVID-19 in the header.

References

Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020 Mar 6. pii: S0092-8674(20)30262-2.

Millet JKTang TNathan LJaimes JAHsu HLDaniel SWhittaker GRProduction of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting. J Vis Exp., 2019 Mar 1;(145).

Millet JK, Whittaker GR. Murine Leukemia Virus (MLV)-based Coronavirus Spike-pseudotyped Particle Production and Infection.  Bio Protoc. 2016 Dec 5;6(23). pii: e2035

Contact

Department of Biology and Chemistry
Paul Scherrer Institute PSI
5232 Villigen-PSI
Switzerland

Scientist
Laboratory of Nanoscale Biology
Dr. Roger Benoit

+41 56 310 47 03
roger.benoit@psi.ch